In the phase III PALOMA-3 study, patients with advanced-stage, hormone receptor positive, ErbB2-negative breast cancer that had progressed after endocrine therapy were assigned for treatment with either the endocrine therapeutic agent fulvestrant alone or in combination with palbociclib [68]. Here, NR4A1 is linked to breast cancer.